NalaGenetics’ Post

The spotlight is on Peter Nestorov and the incredible work of Scailyte in precision medicine, featured at #PMFG2024! Their innovative solutions are shaping the future of #healthcare and #diagnostics. 🚀 It’s always inspiring to see members of our CEO CF community driving such meaningful change. #PrecisionMedicine #Innovation #Leadership #CEOCF

We are excited to share our latest research at the upcoming Health Technology Assessment international (HTAi) 2024 event in Seville! Be sure to mark your calendars and book a #braindate with the presenters. 1. A European Value Assessment Framework For Next Generation Sequencing And Comprehensive Genomic Profiling Oncology Diagnostics - Oral Presentation 🗓 Date & Time: Tuesday, 18 June 2024, 14:35 – 15:35 📍 Location: Room – Andalucia 5, Barceló Convention Centre Description: In a joint collaboration between the MTRG and IECS - Instituto de Efectividad Clínica y Sanitaria, led by Dr Panos Kanavos and Dr Prof. Federico Augustovski, MD, MSc, PhD, we developed a value assessment framework to provide transparent and explicit criteria for the evaluation and coverage of NGS/CGP diagnostics in European oncology settings. Presenter: Madeleine Haig 2. Incentives To Incorporate Innovation Into Care Delivery Processes: A Scoping Review And SWOT Analysis - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: Part of HI-PRIX HORIZON, this research investigates the strengths, weaknesses, opportunities, and threats of financial and non-financial incentive mechanisms that aim to improve access to innovative medical technologies. Presenter: Madeleine Haig 3. Do Patient Contributions Matter? A Thematic Document Analysis of NICE Ultra-Rare Disease Appraisals - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: This study analyses inputs from patient organisations and patient experts in technology appraisals for ultra-rare diseases in the UK and seeks to understand how they are taken into account in NICE final recommendations. Presenter: Arianna Gentilini See you there! #HTAi2024 #healthtechnologyassessment #pharmaceuticalpolicy #NICE #patientorganisations #valueassessment

🏅 We are honoured that our latest research has been selected for a poster presentation at the upcoming 31st European congress on obesity #ECO2024 organized by European Association for the Study of Obesity (EASO). We will be able to present and discuss with researchers, industry representatives and medical doctors about our most recent progress in the application of our patented #ExAdEx technology for #obesity research and #development of novel therapies aimed at stimulating #energy expenditure 🎯 Our work has been performed in collaboration with Antonio Iannelli Centre Hospitalier Universitaire de Nice (CHU de Nice) Docteur Bérengère Chignon Sicard MD PhD Christian DANI Alain DOGLIO, the consortium Adipo-Cible and our partners from IdEx Investissements d'Avenir #France2030, Université Côte d’Azur Clémence Fournier and supported by a #BourseFrenchTechEmergence by Bpifrance. 👩🔬 This work has also allowed us to recently welcome a PhD student Floricia Crusset on a #CIFRE PhD program co-funded by ANRT - Association Nationale de la Recherche et de la Technologie to accelerate the development of obesity clinically-relevant preclinical models of human #adipose tissue in collaboration with IPMC CNRS-U. NICE SOPHIA Georges Vassaux Bernard Mari. 31st European Congress on Obesity G-communication sessions: 📆 May 13-14 2024 📍 Venice, Italy 📖 Donor-derived vascularized organoids modelling inflammation, fibrosis and beiging therapeutical effects of human adipose tissue #pharma #obesity #metabolicdiseases #venice #3Dmodels #preclinical

On Day 1 of #BIO2024 in San Diego, DoH Chairman, H.E. Mansoor Al Mansoori, participated in a panel discussion titled “Global Policy Perspectives on the Next Generation of Rare Disease Medicines”. Moderated by Jannie Oosthuizen, the panel was also attended by Durhane Wong-Rieger, Karin Hoelzer and Ryan MacFarlane. With 2.8 million people affected by rare diseases in the Middle East, H.E. highlighted the significant strides Abu Dhabi is making in the realm of genomic research and gene therapies and the 5 pillars of policy development: 1. Investment in Technology and Innovation: The Emirati Genome Programme has mapped over 500,000 genomes, offering insights into genetic diseases affecting our population. 2. Financial and Policy Support: The DoH partnership with the Ma'an Fund for Research is fostering sustainable funding for innovation with a focus on rare diseases. 3. Advancing Research: Our agile regulatory processes are accelerating clinical trials and personalised medicine. 4. Prevention and Detection: Through screening programmes, we aim to prevent and detect rare diseases early and prevent them altogether. 5. Collaboration: Public-private partnerships, such as those with MSD, are vital in driving innovation and developing effective treatments. The Department of Health – Abu Dhabi is committed to accelerating a future where there are effective treatments – and cures – for many rare diseases. #AHealthierAbuDhabi #Healthcare

The Kineticos AMR Accelerator Fund I envisions a World Without Antimicrobial Resistance. Launched in 2023, KAMRA focuses on supporting innovators to address the serious global problem of AMR. Since then, there is a growing awareness of the AMR issue, as exemplified in recent scientific publications, and the 79th UN General Assembly in September, which called for sustainable national financing to address this urgent healthcare need. Kineticos provides an overview and our comments on the growing awareness in AMR Efforts in Q3. #AMR #antimicrobialresistance https://lnkd.in/eap2SVwa

Excellent success for FIMM researchers in the Research Council of Finland's funding call!   The Research Council of Finland | Suomen Akatemia has granted funding for five new FIMM-driven Academy Projects and for one Clinical Researcher. FIMM warmly congratulates all the grant recipients!   Funded projects: Decoding pan-cancer tumor microenvironment with integrative single-cell spatial profiling Project PIs: Lassi Paavolainen & Teijo Pellinen   Inherited mechanisms of impaired female reproduction – from discovery towards clinical translation Project PI: Elisabeth Widén   Development and prospective validation of a deep learning model to detect abnormal clinical laboratory measurements in the entire Finnish population Project PI: Andrea Ganna   Insulin secretion in type 1, type 2 and monogenic diabetes: effect of genetic variants on the heterogeneity of diabetes Project PI: Tiinamaija Tuomi   Metabolic subphenotyping for improved reclassification of cardiometabolic risk and better response to lifestyle modifications Project PI: Rubina Tabassum   Clinical Researcher Shared heritability of nasal polyps and astma in Finnish biobanks Elmo Saarentaus Read more: https://lnkd.in/dhfG7BuF #research #health #medicine #fundingnews

𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔 𝒇𝒓𝒐𝒎 𝑾𝒊𝒍𝒔𝒐𝒏 𝑨𝒂𝒓𝒉𝒖𝒔 2024 𝑺𝒚𝒎𝒑𝒐𝒔𝒊𝒖𝒎 Steve Hahn, MD, PhD, our Chief Medical Officer and Co-Founder, presented updates on a large 22,000-sample pilot study for modernized newborn screening using Key Proteo’s Immuno-SRM. 𝑲𝒆𝒚 𝑻𝒂𝒌𝒆𝒂𝒘𝒂𝒚𝒔: ▪ APT7B peptide target quantified with very high sensitivity and specificity. ▪ Exceptionally low false positive rate and invalid rate. No true false negatives. ▪ Peptide concentrations stable across weight, gender, and ethnicity. ▪ LC-MS proteomics proven feasible for newborn screening of Wilson Disease from standard DBS specimens. Early detection and intervention is critical. Key Proteo’s Immuno-SRM technology reveals the previously undetectable using existing LC-MS workflows. Key Proteo is grateful to the Wilson Aarhus Symposium for featuring cutting-edge Wilson Disease research. Kudos to all presenters, attendees and organizers! #WilsonDisease #WilsonDiseaseAssociation #MedicalResearch #Proteomics #NewbornScreening #HealthcareInnovation #WilsonAarhus2024 #KeyProteo #EarlyDetection Get in touch with us at info@keyproteo.com www.keyproteo.com

#Review Plasmonic Biosensors for Single-Molecule Biomedical Analysis by Elba Mauriz andLaura M. Lechuga https://lnkd.in/eQ5ZxnVB MDPI Universidad de León Institut Català de Nanociència i Nanotecnologia (ICN2) #singlemoleculeanalysis #biosensors #plasmonics #nanoparticle #nanostructure #nucleicacids #virus #livingcells #openaccess #Abstract The rapid spread of epidemic diseases (i.e., coronavirus disease 2019 (COVID-19)) has contributed to focus global attention on the diagnosis of medical conditions by ultrasensitive detection methods. To overcome this challenge, increasing efforts have been driven towards the development of single-molecule analytical platforms. In this context, recent progress in plasmonic biosensing has enabled the design of novel detection strategies capable of targeting individual molecules while evaluating their binding affinity and biological interactions. This review compiles the latest advances in plasmonic technologies for monitoring clinically relevant biomarkers at the single-molecule level. Functional applications are discussed according to plasmonic sensing modes based on either nanoapertures or nanoparticle approaches. A special focus was devoted to new analytical developments involving a wide variety of analytes (e.g., proteins, living cells, nucleic acids and viruses). The utility of plasmonic-based single-molecule analysis for personalized medicine, considering technological limitations and future prospects, is also overviewed.

Business Models in Pharma and HealthCare sector ➡ The pharmaceutical sector is undergoing a massive transformation, as well as expansion and diversification of products beyond the pill ➡ The digital revolution and technology are undoubtedly the disruptive and driving forces behind this transformation, but they are not the only ones. The holistic approach to medicine and a broader concept of health, which takes into account wellness, or the entry of new players and the creation of new work and business models are also relevant ➡ In this context, Innovation becomes an essential pillar to respond to these challenges and, above all, to transform opportunities into realities A tailor-made training to go deeper into the so-called "P-medicine": Personalized, Preventive, Predictive, Precision, Participatory, Patient-centered, Population-based ---- CAIXA RESEARCH INSTITUTE CaixaResearch Institute, a new health and life sciences research and innovation centre, the first one specialised in immunology in Spain –The CaixaResearch Institute will be dedicated to studying how the immune system works when it interacts with the most prevalent pathologies, such as neurological, oncological and infectious diseases, as well as analysing related environmental factors –Four research centres are part of the initiative as CaixaResearch Associated Centres: the IrsiCaixa AIDS Research Institute, the Barcelona Institute for Global Health (ISGlobal), Vall d'Hebron Institute of Oncology (VHIO)) and the Barcelonaβeta Brain Research Center (BBRC), the research institute of Fundación Pasqual Maragall A pleasure to extend and strengthen my collaboration with the ecosystem Fundación ”la Caixa” Great session with key roles in these organizations: Marina Espriu, Lucie Rabattu, Oscar Casado Vilches, Teresa Puigferrat Pérez, Nestor Huerta Baño, Mario De la Cuesta Rivero, Cristina Val Cid, José Luis Pérez Guillamón, Carolina Minguillon, Paula Mera Nanín, PhD, Mònica Montserrat, Carlos Pérez Flores, Lídia Aguilera, Alba Velasco Trujillo, E. Ramona Popescu, Laurent Ladépêche #innovation #healthcare #pharma #research #science #businessmodels #patients #medicine

NEWS | MiMark diagnostics EndoPath project selected in the InnoBuyer Open Call for EIC Solvers 👉 https://tuit.cat/PQGif Partnering with IDIAPJGol (Institut d'Investigació en Atenció Primària de Salut Jordi Gol) to co-create and pilot a study for the discovery and validation of new biomarkers for endometriosis. And collaborating closely with the Grup de Recerca en Atenció de la Salut Sexual i Reproductiva (GRASSIR) and the Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca, to address the current challenges of the diagnosis of #endometriosis.